CHP investigates case of severe paediatric influenza B infection
The Centre for Health Protection (CHP) of the Department of Health is today (June 5) investigating a severe paediatric influenza B infection case. The CHP urged the public to maintain good personal and environmental hygiene at all times to prevent influenza and other respiratory illnesses.
The case involves a 17-year-old boy with underlying illnesses. He was admitted to Tseung Kwan O Hospital on May 27 due to a fever, vomiting and seizure. His condition gradually improved following treatment. He remained hospitalised and developed a fever again on June 3, accompanied by a cough with blood-stained sputum. He was transferred to the paediatric intensive care unit of United Christian Hospital yesterday (June 4) due to a drop in blood oxygen levels. His respiratoryspecimen collected on June 4 tested positive for the influenza B virus upon laboratory testing. The clinical diagnosis was influenza B infection complicated with severe pneumonia and shock. He remains hospitalised and is in critical condition.
The CHP's preliminary investigation revealed that the boy has not received the 2025/26 seasonal influenza vaccination. He had no travel history and did not attend school during the incubation period. His close contacts remain asymptomatic. No influenza outbreaks have been reported recently at his boarding school. The CHP will continue to investigate the case.
Influenza activity in Hong Kong has increased in recent weeks but remains below the baseline level. Based on past experience, Hong Kong may experience two influenza seasons each year. Last year's summer influenza season began later than usual and lasted longer than normal, extending from early September last year to early January this year, resulting in the absence of the winter influenza season that traditionally occurs in the first quarter of each year. Nearly six months have passed now since the last influenza season. Given that many members of the public have not been infected with the seasonal influenza virus in recent months, it cannot be ruled out that influenza activity may further increase.
The CHP also reminded members of the public that, especially for children, the elderly and those with underlying illnesses, they should seek medical advice promptly for early treatment if they present with fever and respiratory symptoms. As children with influenza can deteriorate rapidly, parents must pay close attention to their children's condition. They should go to an Accident and Emergency Department immediately if the child's condition deteriorates, for example, if they develop symptoms such as shortness of breath, wheezing, blue lips, chest pain, confusion, a persistent fever or convulsions.
Separately, the public should maintain good personal and environmental hygiene at all times to prevent contracting influenza and other respiratory illnesses. High-risk individuals should wear surgical masks when staying in crowded places. People with respiratory symptoms, even if mild, should wear a surgical mask and seek medical advice promptly. They should also consider whether to attend work or school.
Members of the public may refer to the CHP's COVID-19 & Flu Express,Seasonal Influenza Webpage, COVID-19 Vaccination Programme Webpage, and Vaccination Schemes Webpage, for the latest information.
The Centre for Health Protection (CHP), Photo source: reference image
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards
The Department of Health (DH) today (July 14) convened the 14th Meeting of the International Advisory Board (IAB) on Hong Kong Chinese Materia Medica Standards (HKCMMS) to review the reference standards for 16 types of Chinese Materia Medica (CMM) commonly used in Hong Kong, and to discuss the future development of the HKCMMS. Over 60 experts from the Chinese Mainland, overseas and Hong Kong attended the meeting.
Since 2002, the DH has been implementing the HKCMMS project in phases to develop standards for commonly used CMM in Hong Kong to ensure their safety and quality.
In his opening remarks, the Director of Health and the Chairperson of the IAB, Dr Ronald Lam, said, "One of the key initiatives of the Government Chinese Medicines Testing Institute (GCMTI) under the DH is the implementation of the HKCMMS. With the publication of the Volume 12 of the HKCMMS, standards for 357 types of CMM have been established so far. They have become widely recognised international reference standards for Chinese medicine testing and certification, thereby promoting the high-quality scientific development of Chinese medicine. In addition, the work of GCMTI is closely aligned with national priorities. The National 15th Five-Year Plan made it clear that we need to 'advance the inheritance and innovation of Chinese medicine' and 'promote the integration of Chinese and Western medicine'. It also calls for us to 'strengthen the conservation and utilisation of Chinese medicine resources', 'improve the quality of Chinese medicine, and build up and strengthen the Chinese medicine industry'. These are exactly the goals that the HKCMMS Project is helping to achieve - by setting rigorous quality standards for CMM and conducting applied research and development on testing methods that underpin the entire industry, establishing the Hong Kong Special Administrative Region as a bridgehead for the global expansion of Chinese Medicine."
Dr Lam emphasised that the success of the HKCMMS project depends on the active collaboration of stakeholders across different sectors. He expressed his sincere appreciation to the four research partners attending the meeting, commending their dedicated contributions to advancing the project's research efforts. They were the National Institutes for Food and Drug Control, the Chinese University of Hong Kong, the Hong Kong Polytechnic University and the China Medical University. He also thanked the Government Laboratory for conducting inter-laboratory verification studies. Dr Lam emphasised that these collaborations are crucial for establishing a rigorous and solid scientific foundation for the HKCMMS and gaining international credibility. The DH is also deeply grateful to the National Medical Products Administration, the National Administration of Traditional Chinese Medicine and the Chinese Pharmacopoeia Commission for their continuous valuable advice and support in developing the HKCMMS. To align with the National 15th Five-Year Plan to advance the inheritance, innovation and high-quality development of Chinese medicine, expand and promote Chinese medicine culture, the DH will continue to steadfastly promote the development of Chinese medicine and better integrate into and serve the overall national development.
The two-day meeting brought together experts from the Chinese Mainland, Australia, Austria, Canada, Germany, Japan, Thailand, the United Kingdom and the United States, as well as representatives from research institutions, the DH and the Government Laboratory of the Hong Kong Special Administrative Region. The 16 types of CMM commonly used in Hong Kong that were discussed at the meeting included Bambusae Caulis in Taenias, Pyrolae Herba, Natrii Sulfas, Dichroae Radix, Dioscoreae Hypoglaucae Rhizoma, Cynanchi Atrati Radix et Rhizoma, Jasmini Flos, Tinosporae Caulis, Inulae Flos, Haematitum, Lasiosphaera seu Calvatia, Vespae Nidus, Dioscoreae Rhizoma, Aconiti Kusnezoffii Folium, Meliae Cortex and Tripterygii Wilfordii Radix.
Previous editions of the HKCMMS can be accessed at the website of the Chinese Medicine Regulatory Office of the DH.
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases
